Nanoform Signs U.S. Pharma Partnership for Biologics Technology
Nanoform has entered into an exclusivity agreement with a U.S.-based biopharmaceutical company for the application of its biologics nanoparticle technology in the development of subcutaneous
ERS Genomics Signs CRISPR Licensing Agreement with Aurigene Services
ERS Genomics has entered into a non-exclusive licensing agreement with Aurigene Pharmaceutical Services Limited, providing the company access to ERS’ foundational CRISPR/Cas9 intellectual property portfolio.
Vetter Breaks Ground on €500 Million Injectable Drug Facility in Germany
Vetter has started construction of a new production facility in Saarlouis, Germany, marking an expansion of its commercial injectable drug manufacturing operations. The company said
OrganaBio Acquires Excellos to Expand Cell Therapy CDMO Network
OrganaBio has acquired substantially all of the operating assets of Excellos Inc., expanding its cell therapy manufacturing operations and establishing a bicoastal contract development and
How Kindeva’s $200M Sterile Injectable Investment Is Setting a New Compliance Benchmark for CDMOs
“At Kindeva, we want to be viewed as a fully Annex 1 compliant facility and partner that can pivot when needed and supply uninterrupted to
Elpida Therapeutics Selects Catalent for Late-Phase AAV Manufacturing
Elpida Therapeutics and Catalent have announced a strategic partnership focused on late-phase manufacturing support for Elpida’s lead AAV9 gene therapy program targeting Spastic Paraplegia Type
Charles River Laboratories Partners with MEDIPOST on Cell Therapy GMP Testing
Charles River Laboratories and MEDIPOST Co., Ltd. have entered into a non-exclusive memorandum of understanding to collaborate on GMP-compliant testing services and broader commercial and
CDMO consolidation drives PE toward equipment and consumables
This guest editorial was written by Dan Stanton, Trade Media Relations Expert, Sartorius Industry consolidation and the rising cost of entry are driving private equity
ICON Opens 69,500 sq ft Early Phase CRU in San Antonio Alongside New Satellite Outpatient Clinics
ICON plc (NASDAQ: ICLR), a world-leading CRO, has announced the opening of a new, purpose-built Clinical Research Unit in San Antonio, Texas, along with satellite outpatient
Veeda Lifesciences and Agilent Launch Joint CRO Center of Excellence for GLP-1 and Complex Biologics Analytics
Veeda Lifesciences, a leading independent CRO offering clinical, preclinical, and bioanalytical services from India, and Agilent Technologies (NYSE: A) have announced the launch of a